Posted on 1/20/21
Syros Prices of $75.6 Million Public Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has priced an . . .
Posted on 1/20/21
AVEO Oncology Announces Incremental $10M Loan
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC) . . .
Posted on 1/20/21
Here's Why Bristol Myers Squibb's Partners Think 2021 Could Be Prosperous
In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss upcoming . . .
Posted on 1/20/21
Moderna CEO's 9 Words That Could Mean Billions for the Biotech
Moderna (NASDAQ:MRNA) generated revenue of roughly $60 million in 2019. The company will post total revenue measured in the hundreds of millions of dollars for 2020. . . .
Posted on 1/20/21
Fulcrum Therapeutics Prices of Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically . . .
Posted on 1/20/21
TCR Therapeutics Prices Public Offering of $140.0 Million of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for . . .
Posted on 1/20/21
Editas Medicine Announces Offering of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and . . .
Posted on 1/20/21
Syros Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell . . .
Posted on 1/19/21
Fulcrum Therapeutics Proposes Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically . . .
Posted on 1/19/21
Thermo Fisher Scientific to Acquire Mesa Biotech
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc.,
Posted on 1/19/21
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to . . .
Posted on 1/19/21
Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty . . .
Posted on 1/19/21
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma
Posted on 1/19/21
TCR² Therapeutics Proposes Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for . . .
Posted on 1/19/21
Beam Therapeutics Announces $260 Million Common Stock Investment from Multiple Investors
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that . . .
Posted on 1/19/21
Verve Therapeutics Closes $94 Million Series B
Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced the successful completion of a $94 million Series B financing, led . . .
Posted on 1/19/21
Can the Pfizer and Moderna Vaccines Beat the New Coronavirus Strains?
Investors in Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) may have breathed a sigh of relief when the U.S. Food and Drug Administration granted the companies' coronavirus vaccines . . .
Posted on 1/19/21
Better Buy: Novavax vs. Moderna
Here's a story of two biotechs. Both of them scrambled to develop COVID-19 vaccines last year. One of them, Moderna (NASDAQ:MRNA), ranked as one of the . . .
Posted on 1/19/21
This Is the Best News Yet for Moderna's COVID Vaccine
Moderna (NASDAQ:MRNA) has announced its share of good news in the past couple of months. The biotech company generated positive results in the phase 3 trial . . .
Posted on 1/15/21
Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project
Genetic testing expert Invitae (NYSE:NVTA) has received the backing of some of the largest pharmaceutical companies in the industry. Bristol Myers Squibb (NYSE:BMY), Johnson & Johnson . . .
Posted on 1/15/21
Moderna to Test Coronavirus Vaccine Booster Shot in New Clinical Trial
The first jab of Moderna's (NASDAQ:MRNA) two-shot coronavirus vaccine hasn't made it into the arms of the millions who will eventually receive it, but the company . . .
Posted on 1/15/21
Orthus Health Partners With Healbright To Expand Mental Health Offering
Orthus Health, a leading corporate wellness and condition management company, has partnered with Healbright, a Boston-based leading provider of online mental health services. The partnership will . . .
Posted on 1/14/21
Is Moderna Stock Overvalued?
Moderna(NASDAQ:MRNA) ranks as one of the biggest winners of the coronavirus vaccine race. The stock has skyrocketed, but has it gone up too much? In this . . .
Posted on 1/14/21
Aldeyra Therapeutics Prices Public Offering of Common Stock
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives . . .
Posted on 1/14/21
Disc Medicine Appoints William White to its Board of Directors
Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates
Boston
